AIDS-Related Kaposi Sarcoma
14
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.3%
2 terminated out of 14 trials
77.8%
-8.7% vs benchmark
14%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Nirogacestat in Patients With Kaposi Sarcoma
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Doxil/Caelyx BE Study
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma